ARCT Earnings Prediction
The chart below shows how ARCT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ARCT sees a +0.67% change in stock price 10 days leading up to the earnings, and a +7.26% change 10 days following the report. On the earnings day itself, the stock moves by -2.01%. This data can give you a slight idea of what to expect for the next quarter's release.
ARCT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
41.67M
-7.68%
-16.42%
Gross Margin
--
--
--
Operating Margin
-25.76%
-39.80%
-39.20%
Net Margin
-16.56%
-53.92%
-52.04%
EPS
-0.26
-57.38%
-59.38%
No Data Available
ARCT Earnings Analysis
Arcturus Therapeutics Holdings Inc. Common Stock Corporation (ARCT.O) Earnings Conference Call
Positive
Product Launch Milestone: The company achieved a significant milestone with the commercial launch of KOSTAIVE in Japan, marking its first commercial product in history.
Milestone Payment Achievement: ArcTurus received a $25 million commercial milestone payment following the first sale of KOSTAIVE in Japan.
Operating Expenses Reduction: Total operating expenses for Q3 2024 were $52.4 million, a decrease from $64.5 million in Q3 2023, indicating improved cost management.
R&D Expense Reduction: Research and development expenses decreased to $39.1 million for Q3 2024 compared to $51.1 million for Q3 2023, reflecting efficient resource allocation.
Strong Cash Position: The company reported cash and cash equivalents of $294.1 million as of September 30, 2024, demonstrating a strong financial position.
Negative
Revenue Decrease Analysis: For the three months ended September 30th, 2024, we reported revenues of $41.7 million, a slight decrease from the $45.1 million reported in the same period in 2023.
Revenue Decrease Analysis: This small decrease is attributable to a decrease in CSL revenue as we achieved a milestone of $35 million during Q3 of 2023 compared to a milestone of $25 million during Q3 of 2024.
Operating Expenses Comparison: Total operating expenses for Q3 2024 were $52.4 million compared with $64.5 million for Q3 2023.
R&D Expense Comparison: Research and development expenses with $39.1 million for Q3 2024 compared with $51.1 million for Q3 2023.
Manufacturing Expense Decrease: The decrease was primarily due to $15.9 million in manufacturing expenses incurred in the Q3 2023 related to the Meiji supply agreement and other clinical trials manufacturing batches as well as decreased facilities and equipment expenses.
ARCT FAQs
How does ARCT typically perform around its earnings report dates?
Is Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ARCT Earning Call Sentiment
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ARCT.O
-0.59%Positive
The earnings call highlights significant achievements, such as a commercial milestone for KOSTAIVE in Japan and a strong cash position, despite a slight revenue decline. The Q&A suggests optimism about future launches and expansions, though management was vague on some specifics. The positive guidance and strategic developments, like the KOSTAIVE launch and new studies, outweigh the concerns, indicating a likely positive stock price movement in the short term.
